SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is caught in a broader memory-stock selloff, with traders focused on concerns that Chinas CXMT could add competition and pressure sector pricing, alongside wider worries about AI valuations and macro conditions. The community is split between expecting further declines and viewing the China threat as overstated, arguing that SanDisks NAND business differs from CXMTs DRAM focus and that AI-related storage demand remains supportive.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMCs Q3 results beat expectations and set records, reinforcing the view that AI-chip demand remains strong. Traders are divided on the market reaction: some see the report as validation of the AI semiconductor cycle, while others point to a sell-the-news move and broader risk-off pressure weighing on shares despite the strong results.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Hotter-than-expected inflation has revived fears of further Fed rate hikes, alongside a selloff in AI and semiconductor stocks that is weighing on the broader index. Traders are split between viewing the decline as a buying opportunity and warning of a deeper correction, with upcoming inflation data in focus.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDA expanded Anktivas approval to cover BCG-unresponsive papillary-only non-muscle-invasive bladder cancer, broadening the treatments eligible patient population ahead of the agencys target date. Traders largely welcomed the decision as a meaningful commercial and regulatory milestone, though many were disappointed by the stocks muted response and debated whether the news was already priced in amid concerns about valuation and potential dilution.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is under pressure amid a sharp South Korean semiconductor selloff, with traders citing fears of rising Chinese memory-chip competition, doubts about AI spending and broader macro concerns. Bulls argue the CXMT threat is overstated and view the pullback as a buying opportunity, while bears warn that competition and memory-cycle risks could prolong the decline.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a broad technology and semiconductor selloff, with traders citing hotter-than-expected inflation and renewed fears of Federal Reserve rate hikes; weakness in South Korean markets and concerns about AI spending have added to the unease. The community is split between expecting further losses and viewing the pullback as a buying opportunity, with upcoming inflation data seen as a potential catalyst for direction.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is centered on Gartners warning that many neocloud providers may not remain independent, alongside concerns that the companys debt-heavy expansion could become harder to finance as its bond yields rise and inflation fuels rate worries. Traders are divided between fears of financial distress and an AI infrastructure downturn, and dip buyers who point to demand, backlog, and potential Nvidia support.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is under pressure after pushing Neutrons first flight to 2027 because of carbon-composite tank manufacturing issues. Traders are split between viewing the delay as prudent quality control and seeing it as another execution setback that postpones growth; some consider the selloff an overreaction, while broader weakness in space stocks is also mentioned.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is sliding amid a sharp KOSPI selloff led by weakness in Samsung and SK Hynix, with traders citing concerns about Chinese memory-chip competition and foreign investor selling. The community is split between expecting further losses and buying an oversold dip, while noting that the ETFs 3x leverage magnifies the swings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff is weighing on SOXL amid hotter-than-expected inflation and concerns about interest rates, AI spending, and Chinese chip competition; the ETFs three-times leverage is amplifying the swings. Traders are split between treating the drop as an overdone, buy-the-dip pullbackciting strong chip demand and earningsand expecting more downside as selling pressure persists.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market capitalization ofread more...

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an annualized basis producing an average annual return of 29.64%. Currently, Ascendis Pharma has a market capitalization ofread more...

Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock

Mads Bodenhoff, SVP & PAO at Ascendis Pharma (NASDAQ:ASND), reported an insider sell on September 9, according to a new SEC filing.
What Happened: Bodenhoff's decision to sell 3,000 shares of Ascendis Pharmaread more...

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged

Equity

BioMarin and Ascendis settled a global patent dispute over the achondroplasia drug Yuviwel on Sunday. 

Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday.

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)read more...

FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.

• Reported GAAP EPS of $3.22 up 603.12% YoY
• Reported revenue of $339.29M up 114.68% YoY

Ascendis Pharma faces material risks from regulatory review timelines for YUVIWEL, potential reimbursement and pricing challenges for its product portfolio, and dependencies on third-party manufacturing and logistics for commercial operations.

Ascendis Pharma delivered strong 105% year-over-year product revenue growth in Q2 2026 and achieved profitability, supported by robust demand for its TransCon commercial products and continued advancement of its clinical pipeline.

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Bearish Sentiment

Hotter than expected

As expected

Cooler than expected

The September Producer Price Index report lands Thursday, October 15 at 8:30 AM ET, one day after CPI, with August’s reading at 5.4% year over year, as investors look for clues on inflation before the Fed’s October 27-28 meeting. How will the September PPI print compare to consensus expectations? Vote and explain your reasoning in the comments.

How will the September PPI print compare to consensus expectations?

Stocktwits

Stocktwits Polls

Ascendis Pharma

$ASND three wave corrective-looking pullback from the July high may be complete at the Fib .786 retracement level, with bullish divergences on the technical indicators

Feed

News

Sentiment

Earnings

Fundamentals

Info

ASND Ascendis Pharma

Fundamentals

Latest ASND News